Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Dermatology, Immunology +14

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 860 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof et al. · New England Journal of Medicine · 2010 · 851 citations

Medicine, Dermatology, Pharmacotherapy +13

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10